The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed because of a cast error
Error code: DatasetGenerationCastError
Exception: DatasetGenerationCastError
Message: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 10 new columns ({'mutant_rank', 'mut_Rank_Stab', 'mut_netchop_score_ct', 'mutant_rank_PRIME', 'mutant_other_significant_alleles', 'mutant_seq', 'seq_len', 'TAP_score', 'mutant_rank_netMHCpan', 'wt_seq'}) and 31 missing columns ({'HLA', 'anchor_mutation', 'pubmed_id', 'genomic_coord', 'mt_peptide', 'netmhcpan_rank', 'tumor_type_detail', 'netmhcstabpan_stability', 'length', 'effector_origin', 'wt_peptide', 'assay_type', 'dai_netmhcpan', 'bigmhc_im_score', 'mutation_type', 'presentation_method', 'ndd_id', 'reference_name', 'ref', 'eluted_ligand_match', 'position', 'tcga_cancer_expression_tpm_median', 'mutation', 'alt', 'prime_rank', 'driver_status', 'chromosome', 'tap_score', 'stimulation_target', 'tumor_tissue', 'netchop_score'}).
This happened while the csv dataset builder was generating data using
hf://datasets/NeoDiscovery/NDD/data/leaderboard/nip_leaderboard_train.tsv (at revision f4d033289b4846e6a9bc50efd5ed847e438bdd2e)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
Traceback: Traceback (most recent call last):
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1831, in _prepare_split_single
writer.write_table(table)
File "/usr/local/lib/python3.12/site-packages/datasets/arrow_writer.py", line 714, in write_table
pa_table = table_cast(pa_table, self._schema)
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2272, in table_cast
return cast_table_to_schema(table, schema)
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2218, in cast_table_to_schema
raise CastError(
datasets.table.CastError: Couldn't cast
patient_id: string
response_type: string
gene: string
mutant_seq: string
wt_seq: string
seq_len: int64
mutant_rank_netMHCpan: double
mutant_rank: double
mutant_other_significant_alleles: int64
mutant_rank_PRIME: double
TAP_score: double
mut_Rank_Stab: double
mut_netchop_score_ct: double
-- schema metadata --
pandas: '{"index_columns": [{"kind": "range", "name": null, "start": 0, "' + 1909
to
{'ndd_id': Value('string'), 'patient_id': Value('string'), 'tumor_tissue': Value('string'), 'tumor_type_detail': Value('string'), 'gene': Value('string'), 'mutation_type': Value('string'), 'mutation': Value('string'), 'position': Value('string'), 'mt_peptide': Value('string'), 'wt_peptide': Value('string'), 'length': Value('int64'), 'chromosome': Value('string'), 'genomic_coord': Value('string'), 'ref': Value('string'), 'alt': Value('string'), 'HLA': Value('string'), 'response_type': Value('string'), 'assay_type': Value('string'), 'effector_origin': Value('string'), 'stimulation_target': Value('string'), 'presentation_method': Value('string'), 'netmhcpan_rank': Value('float64'), 'netmhcstabpan_stability': Value('float64'), 'prime_rank': Value('float64'), 'bigmhc_im_score': Value('float64'), 'tap_score': Value('float64'), 'netchop_score': Value('float64'), 'dai_netmhcpan': Value('float64'), 'anchor_mutation': Value('string'), 'eluted_ligand_match': Value('int64'), 'tcga_cancer_expression_tpm_median': Value('float64'), 'driver_status': Value('string'), 'pubmed_id': Value('string'), 'reference_name': Value('string')}
because column names don't match
During handling of the above exception, another exception occurred:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1455, in compute_config_parquet_and_info_response
parquet_operations = convert_to_parquet(builder)
^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1054, in convert_to_parquet
builder.download_and_prepare(
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 894, in download_and_prepare
self._download_and_prepare(
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 970, in _download_and_prepare
self._prepare_split(split_generator, **prepare_split_kwargs)
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1702, in _prepare_split
for job_id, done, content in self._prepare_split_single(
^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1833, in _prepare_split_single
raise DatasetGenerationCastError.from_cast_error(
datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 10 new columns ({'mutant_rank', 'mut_Rank_Stab', 'mut_netchop_score_ct', 'mutant_rank_PRIME', 'mutant_other_significant_alleles', 'mutant_seq', 'seq_len', 'TAP_score', 'mutant_rank_netMHCpan', 'wt_seq'}) and 31 missing columns ({'HLA', 'anchor_mutation', 'pubmed_id', 'genomic_coord', 'mt_peptide', 'netmhcpan_rank', 'tumor_type_detail', 'netmhcstabpan_stability', 'length', 'effector_origin', 'wt_peptide', 'assay_type', 'dai_netmhcpan', 'bigmhc_im_score', 'mutation_type', 'presentation_method', 'ndd_id', 'reference_name', 'ref', 'eluted_ligand_match', 'position', 'tcga_cancer_expression_tpm_median', 'mutation', 'alt', 'prime_rank', 'driver_status', 'chromosome', 'tap_score', 'stimulation_target', 'tumor_tissue', 'netchop_score'}).
This happened while the csv dataset builder was generating data using
hf://datasets/NeoDiscovery/NDD/data/leaderboard/nip_leaderboard_train.tsv (at revision f4d033289b4846e6a9bc50efd5ed847e438bdd2e)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
ndd_id
string | patient_id
string | tumor_tissue
string | tumor_type_detail
string | gene
string | mutation_type
string | mutation
string | position
string | mt_peptide
string | wt_peptide
string | length
int64 | chromosome
string | genomic_coord
string | ref
string | alt
string | HLA
string | response_type
string | assay_type
string | effector_origin
string | stimulation_target
string | presentation_method
string | netmhcpan_rank
float64 | netmhcstabpan_stability
float64 | prime_rank
float64 | bigmhc_im_score
float64 | tap_score
float64 | netchop_score
float64 | dai_netmhcpan
float64 | anchor_mutation
string | eluted_ligand_match
int64 | tcga_cancer_expression_tpm_median
float64 | driver_status
string | pubmed_id
string | reference_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NDDR-8Y7QQTRFWC-U
|
GEXOATK7
|
Skin
|
Skin Cutaneous Melanoma
|
WDR46
|
SNV
|
p.T227I
|
3
|
FLIYLDVSV
|
FLTYLDVSV
| 9
|
6
|
33287207
|
G
|
A
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC, tumor_cells
|
none
| 0.123
| 0.17
| 0.124
| 0.500021
| 0.2
| 0.152263
| -0.198451
|
no
| 1
| 5.306263
| null |
PMID:33303615
|
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
|
NDDR-2HJHFX0EFJ-0
|
GEXOATK7
|
Skin
|
Skin Cutaneous Melanoma
|
AHNAK
|
SNV
|
p.S4460F
|
1
|
FMPDFDLHL
|
SMPDFDLHL
| 9
|
11
|
62526678
|
G
|
A
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS, multimer
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.057
| 0.3
| 0.053
| 0.582847
| 0.782
| 0.978539
| -0.816761
|
no
| 1
| 4.897806
|
Other Tumor Driver
|
PMID:33303615
|
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
|
NDDR-M2GXDWKP1W-D
|
ZWHDI5GT
|
Skin
|
Skin Cutaneous Melanoma
|
GNB5
|
SNV
|
p.P377L
|
9
|
RVSTLRVSL
|
RVSTLRVSP
| 9
|
15
|
52124519
|
G
|
A
|
HLA-B07:02
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.139
| 0.8
| 0.088
| 0.476441
| 1.286
| 0.034531
| -3.435379
|
no
| 0
| 0.389732
| null |
PMID:33303615
|
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
|
NDDR-JRGCAYDCQA-S
|
6FHDB5EK
|
Skin
|
Skin Cutaneous Melanoma
|
TRAPPC1
|
SNV
|
p.R129G
|
4
|
FRSGLDSYV
|
FRSRLDSYV
| 9
|
17
|
7930659
|
G
|
C
|
HLA-C06:02
|
CD8
|
51Cr, HLA-block
|
patient_Tc_line
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.1
| 29
| 0.018
| 0.380201
| 0.366
| 0.73499
| -0.41871
|
no
| 1
| 5.942411
| null |
PMID:10582700
|
Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation
|
NDDR-VXMQ2DHCNY-F
|
DAXCBTFA
|
Skin
|
Skin Cutaneous Melanoma
|
TRAPPC1
|
SNV
|
p.R129G
|
7
|
SELFRSGLDSY
|
SELFRSRLDSY
| 11
|
17
|
7930659
|
G
|
C
|
HLA-B44:02
|
CD8
|
51Cr, HLA-block
|
patient_Tc_line
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.266
| 0.4
| 0.581
| 0.052169
| 3.04
| 0.763436
| 0.158546
|
no
| 1
| 5.942411
| null |
PMID:10582700
|
Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation
|
NDDR-AHCH9CD88T-A
|
M4HZA63S
|
Skin
|
Skin Cutaneous Melanoma
|
HERV-K-MEL
|
SNV
|
p.V102I
|
5
|
MLAVISCAV
|
MLAVVSCAV
| 9
| null | null | null | null |
HLA-A02:01
|
CD8
|
51Cr, HLA-block
|
patient_Tc_line
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 1.022
| 0.3
| 0.553
| 0.416587
| 0.378
| null | -0.068993
|
no
| 0
| null | null |
PMID:12359761
|
A human endogenous retroviral sequence encoding an antigen recognized on Melanoma by cytolytic T lymphocytes
|
NDDR-MG2GYB7FKK-1
|
LFXUCEDT
|
Skin
|
Skin Cutaneous Melanoma
|
PRDX5
|
SNV
|
p.S79L
|
6
|
LLLDDLLVSI
|
LLLDDSLVSI
| 10
|
11
|
64321032
|
C
|
T
|
HLA-A02:01
|
CD8
|
51Cr, HLA-block, multimer
|
patient_Tc_line, patient_TIL
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.171
| 0.4
| 0.046
| 0.535931
| 0.624
| 0.954141
| 0.047913
|
no
| 1
| 7.68365
| null |
PMID:15695408
|
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic Melanoma and targeted by CD8(+) T cells with a memory phenotype
|
NDDR-3Q45K91QR4-F
|
D35NTCNS
|
Skin
|
Skin Cutaneous Melanoma
|
MYO1B
|
SNV
|
p.E911K
|
1
|
KINKNPKYK
|
EINKNPKYK
| 9
|
2
|
191414079
|
G
|
A
|
HLA-A03:01
|
CD8
|
51Cr, HLA-block, multimer
|
patient_Tc_line, patient_TIL
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.024
| 0.2
| 0.013
| 0.446357
| 0.552
| 0.634706
| -4.044512
|
no
| 1
| 3.642422
| null |
PMID:10064075
|
A natural cytotoxic T cell response in a spontaneously regressing human Melanoma targets a neoantigen resulting from a somatic point mutation
|
NDDR-7SABVDNYFG-Y
|
TSXDFNM6
|
Head & Neck
|
Head and Neck Squamous Cell Carcinoma
|
TP53
|
SNV
|
p.Y220C
|
4
|
VVPCEPPEV
|
VVPYEPPEV
| 9
| null | null | null | null |
HLA-A02:01
|
CD8
|
51Cr, HLA-block
|
patient_Tc_line
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.751
| 9
| 1.073
| 0.317315
| 0.454
| 0.687508
| 0.629941
|
no
| 1
| 3.293914
|
Tumor Driver
|
PMID:17294448
|
Immunological characterization of missense mutations occurring within cytotoxic T cell defined p53 epitopes in HLA A0201 squamous cell carcinomas of the head and neck
|
NDDR-GSSA542C57-I
|
7LJZLSYK
|
Skin
|
Skin Cutaneous Melanoma
|
ENTPD4
|
SNV
|
p.P85L
|
7
|
ATDTNNLNVNY
|
ATDTNNPNVNY
| 11
|
8
|
23447838
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
none
| 2.391
| 4.5
| 1.282
| 0.364496
| 2.864
| 0.96242
| 0.671223
|
no
| 0
| 3.119629
| null |
PMID:33038342
|
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|
NDDR-SGEY1B756Q-7
|
7LJZLSYK
|
Skin
|
Skin Cutaneous Melanoma
|
TTC37
|
SNV
|
p.A692V
|
6
|
YLDGKVVDY
|
YLDGKAVDY
| 9
|
5
|
95520755
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
none
| 3.937
| 35
| 11.33
| 0.307559
| 2.426
| null | -0.116625
|
no
| 0
| 3.005436
| null |
PMID:33038342
|
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
|
NDDR-WSV1MDSJB6-H
|
TFT6DO6A
|
Skin
|
Skin Cutaneous Melanoma
|
ARMT1
|
SNV
|
p.P286L
|
2
|
FYGKTILWF
|
FPGKTILWF
| 9
|
6
|
151468641
|
C
|
T
|
HLA-A24:02
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.052
| 0.25
| 0.02
| 0.351818
| 2.108
| null | -4.193145
|
no
| 0
| 2.896756
| null |
PMID:30880120
|
Identification of a neoantigen epitope in a Melanoma patient with good response to anti-PD-1 antibody therapy
|
NDDR-XMMWH86R9X-E
|
FNWFEVPE
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
PDCD10
|
SNV
|
p.A74P
|
4
|
IASPIKEL
|
IASAIKEL
| 8
|
3
|
167687680
|
C
|
G
|
HLA-C12:02
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.234
| 2.5
| 3.957
| 0.149582
| 0.99
| 0.48951
| -1.082819
|
no
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-BBEYF3X3HN-4
|
FNWFEVPE
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
PDCD10
|
SNV
|
p.A74P
|
10
|
LQTIKDIASPI
|
LQTIKDIASAI
| 11
|
3
|
167687680
|
C
|
G
|
HLA-B52:01
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 7.046
| 0.4
| 10.695
| 0.000387
| 0.728
| 0.897295
| 0.649004
|
no
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-8FNTWKZDFG-Y
|
FU5SPZUA
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
TSEN54
|
SNV
|
p.R472Q
|
2
|
AQMCISGF
|
ARMCISGF
| 8
|
17
|
75523764
|
G
|
A
|
HLA-C12:03
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 22.864
| 1.2
| 33.066
| 0.003008
| 3.142
| 0.307014
| -0.193672
|
yes
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-JDQYDNJXFT-A
|
FU5SPZUA
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
PCSK9
|
SNV
|
p.V202F
|
11
|
DHREIEGRVMF
|
DHREIEGRVMV
| 11
|
1
|
55052358
|
G
|
T
|
HLA-B18:01
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.158
| 12
| 1.548
| 0.145635
| 2.264
| 0.536006
| -2.522178
|
no
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-0J9XF0AJTT-A
|
FU5SPZUA
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
PCSK9
|
SNV
|
p.V202F
|
1
|
FTDFENVP
|
VTDFENVP
| 8
|
1
|
55052358
|
G
|
T
|
HLA-C05:01
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 9.493
| 45
| 8.173
| 0.146671
| -0.474
| 0.405231
| -0.296779
|
no
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-0V67NT0BT2-D
|
FU5SPZUA
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
NEU2
|
SNV
|
p.L234T
|
9
|
KTGEQRVVTL
|
KTGEQRVVLL
| 10
|
2
|
233034587
|
G
|
A
|
HLA-C12:03
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 9.571
| 5.5
| 5.727
| 0.004257
| 0.814
| null | -0.381034
|
yes
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-9A9KVDPVGD-V
|
FU5SPZUA
|
Cerebellum/Posterior fossa
|
Medulloblastoma (pediatric)
|
SVIL
|
SNV
|
p.D1285N
|
8
|
RTDVKAYNVT
|
RTDVKAYDVT
| 10
| null | null | null | null |
HLA-C05:01
|
CD8
|
ELISPOT, ICS, multimer
|
patient_Tc_line, PBMC_pre
|
peptide_pulsed_APC
|
none
| 12.052
| 31
| 3.575
| 0.175771
| -0.81
| 0.027018
| -0.39557
|
no
| 0
| null | null |
PMID:31351799
|
Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
|
NDDR-NB93YAHBJ0-B
|
4V2JUJEQ
|
Liver
|
Hepatocellular Carcinoma
|
C5orf42
|
SNV
|
p.I1134K
|
13
|
DADILSETFQLLK
|
DADILSETFQLLI
| 13
|
5
|
37201697
|
A
|
T
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_Tc_line
|
peptide_pulsed_APC
|
none
| 12.983
| 5.5
| 2.664
| 0.158422
| null | null | -1.87901
|
no
| 0
| null | null |
PMID:31887370
|
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
|
NDDR-1YAP0FVN2C-U
|
4V2JUJEQ
|
Liver
|
Hepatocellular Carcinoma
|
C5orf42
|
SNV
|
p.I1134K
|
11
|
DILSETFQLLK
|
DILSETFQLLI
| 11
|
5
|
37201697
|
A
|
T
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_Tc_line
|
peptide_pulsed_APC
|
none
| 3.101
| 1.8
| 0.978
| 0.09474
| 0.296
| null | -2.96262
|
no
| 0
| null | null |
PMID:31887370
|
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
|
NDDR-0T85G4PK4N-4
|
4V2JUJEQ
|
Liver
|
Hepatocellular Carcinoma
|
C5orf42
|
SNV
|
p.I1134K
|
10
|
ILSETFQLLK
|
ILSETFQLLI
| 10
|
5
|
37201697
|
A
|
T
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_Tc_line
|
peptide_pulsed_APC
|
none
| 0.675
| 0.5
| 0.762
| 0.072464
| 0.432
| null | -3.858778
|
no
| 0
| null | null |
PMID:31887370
|
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
|
NDDR-JPW6QH0ZNW-D
|
4V2JUJEQ
|
Liver
|
Hepatocellular Carcinoma
|
C5orf42
|
SNV
|
p.I1134K
|
9
|
LSETFQLLK
|
LSETFQLLI
| 9
|
5
|
37201697
|
A
|
T
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre, patient_Tc_line
|
peptide_pulsed_APC
|
none
| 0.544
| 1.2
| 0.28
| 0.121928
| 0.316
| null | -3.752958
|
no
| 0
| null | null |
PMID:31887370
|
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
|
NDDR-NPWGNEDF13-E
|
G4ZPYEDM
|
Skin
|
Skin Cutaneous Melanoma
|
DDX3X
|
SNV
|
p.E388K
|
4
|
FPKKIQMLA
|
FPKEIQMLA
| 9
|
X
|
41345316
|
G
|
A
|
HLA-B56:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.006
| 0.07
| 0.347
| 0.831153
| -1.374
| 0.920179
| 0.405465
|
no
| 0
| 4.161428
|
Tumor Driver
|
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-1RZ65VX580-B
|
G4ZPYEDM
|
Skin
|
Skin Cutaneous Melanoma
|
ITGA9
|
SNV
|
p.L548P
|
7
|
VTEKLQPTY
|
VTEKLQLTY
| 9
|
3
|
37542539
|
T
|
C
|
HLA-A01:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.02
| 0.12
| 0.02
| 0.281449
| 2.714
| 0.946856
| 1.609438
|
no
| 0
| 1.3091
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-5NDTKW9WVC-U
|
G6DBM54G
|
Skin
|
Skin Cutaneous Melanoma
|
VPS16
|
SNV
|
p.S404F
|
5
|
LRAAFFGKCF
|
LRAASFGKCF
| 10
|
20
|
2862814
|
C
|
T
|
HLA-B27:05
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 2.327
| 0.8
| 0.612
| 0.411294
| 2.934
| 0.412664
| -0.018732
|
no
| 0
| 3.703167
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-MHSQEBMGSW-D
|
G6DBM54G
|
Skin
|
Skin Cutaneous Melanoma
|
CIT
|
SNV
|
p.P2056L
|
4
|
VRTLLSQVNK
|
VRTPLSQVNK
| 10
|
12
|
119690296
|
G
|
A
|
HLA-B27:05
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.829
| 0.4
| 1.059
| 0.659847
| 0.756
| 0.817271
| 0.578183
|
no
| 0
| 0.65081
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-M431P5K4KM-3
|
G6DBM54G
|
Skin
|
Skin Cutaneous Melanoma
|
CASP1
|
SNV
|
p.P172S
|
8
|
WRNILLLSLH
|
WRNILLLPLH
| 10
|
11
|
105041480
|
G
|
A
|
HLA-B27:05
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 2.113
| 1.2
| 0.462
| 0.79588
| -0.566
| null | -0.025235
|
no
| 0
| 2.91849
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-YZD3GSV3PV-C
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
FAM200A
|
SNV
|
p.S116F
|
9
|
IPLSDNTIF
|
IPLSDNTIS
| 9
|
7
|
99548061
|
G
|
A
|
HLA-B35:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.049
| 0.12
| 0.039
| 0.542263
| 1.964
| 0.042772
| -4.541121
|
yes
| 0
| 1.976985
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-QFKBAJAWPA-S
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
GRIN2B
|
SNV
|
p.E1104K
|
5
|
REFDKIELAY
|
REFDEIELAY
| 10
|
12
|
13563928
|
C
|
T
|
HLA-B41:02
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.527
| 2.5
| 0.137
| 0.473416
| 3.384
| 0.977014
| -0.564753
|
no
| 0
| -7.861448
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-3FYD6RDVNQ-7
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
TBX4
|
SNV
|
p.S271F
|
5
|
YPVIFKSIM
|
YPVISKSIM
| 9
|
17
|
61480110
|
C
|
T
|
HLA-B35:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.083
| 0.08
| 0.076
| 0.853465
| -0.268
| 0.949069
| 0.170345
|
yes
| 0
| -5.357024
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-J3PXJHBAC2-D
|
URSBQAUG
|
Skin
|
Skin Cutaneous Melanoma
|
FAM50B
|
SNV
|
p.E78K
|
7
|
DMKARQKALV
|
DMKARQEALV
| 10
|
6
|
3850043
|
G
|
A
|
HLA-B08:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.843
| 3
| 3.24
| 0.65091
| 0.1
| 0.521495
| 0.064934
|
yes
| 0
| 2.637761
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-BGT2WPZEN8-J
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
COL22A1
|
SNV
|
p.D291N
|
7
|
FPQGLPNEY
|
FPQGLPDEY
| 9
|
8
|
138826756
|
C
|
T
|
HLA-B35:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.003
| 0.09
| 0.016
| 0.566362
| 2.026
| 0.818258
| 0
|
yes
| 0
| 0.919263
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-51YCQP8A9M-3
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
COL22A1
|
SNV
|
p.D291N
|
3
|
LPNEYAFVTT
|
LPDEYAFVTT
| 10
|
8
|
138826756
|
C
|
T
|
HLA-B35:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 4.521
| 1
| 0.237
| 0.364148
| -1.422
| 0.05056
| 0.028721
|
yes
| 0
| 0.919263
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-B7GMHB69XA-S
|
F3XRZQLP
|
Skin
|
Skin Cutaneous Melanoma
|
COL22A1
|
SNV
|
p.D291N
|
3
|
LPNEYAFVT
|
LPDEYAFVT
| 9
|
8
|
138826756
|
C
|
T
|
HLA-B35:01
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
TMC
| 0.923
| 0.5
| 0.19
| 0.718165
| -1.422
| 0.499
| -0.327767
|
yes
| 0
| 0.919263
| null |
PMID:28678778
|
An immunogenic personal neoantigen vaccine for patients with Melanoma
|
NDDR-2YDKRK2AD9-K
|
NGE5BUYC
|
Skin
|
Skin Cutaneous Melanoma
|
TTBK2
|
SNV
|
p.S1088L
|
9
|
RPHHDQRSL
|
RPHHDQRSS
| 9
|
15
|
42745988
|
G
|
A
|
HLA-B07:02
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.008
| 0.05
| 0.1
| 0.729896
| 0.654
| 0.118015
| -4.77702
|
no
| 0
| 0.111698
| null |
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-VAPV22ZYG6-H
|
LC3W5VRX
|
Skin
|
Skin Cutaneous Melanoma
|
KIF26B
|
SNV
|
p.N256S
|
2
|
SSYTGFANK
|
SNYTGFANK
| 9
|
1
|
245367135
|
A
|
G
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.007
| 0.3
| 0.006
| 0.334228
| 0.99
| 0.970843
| -4.330733
|
no
| 0
| 1.124709
| null |
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-KWE7NJQDW7-I
|
LYXKV47S
|
Skin
|
Skin Cutaneous Melanoma
|
SPOP
|
SNV
|
p.N147I
|
7
|
FLLDEAIGL
|
FLLDEANGL
| 9
|
17
|
49619021
|
T
|
A
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.009
| 0.8
| 0.042
| 0.644657
| 0.738
| 0.943178
| -0.893818
|
no
| 1
| 2.900451
|
Other Tumor Driver
|
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-KYVW6EZ6RX-E
|
OKQRI23E
|
Skin
|
Skin Cutaneous Melanoma
|
NARFL
|
SNV
|
p.E62K
|
1
|
KSQREEVRR
|
ESQREEVRR
| 9
| null | null | null | null |
HLA-A31:01
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.411
| 1.3
| 0.683
| 0.025452
| 1.666
| null | -2.183067
|
no
| 0
| null | null |
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-NFN8N8118Y-F
|
VU5HBL4S
|
Skin
|
Skin Cutaneous Melanoma
|
PPFIA4
|
SNV
|
p.S709N
|
4
|
MRMNQGVCC
|
MRMSQGVCC
| 9
|
1
|
203053848
|
G
|
A
|
HLA-B39:06
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.418
| 0.09
| 3.039
| 0.972498
| 0.486
| 0.033837
| 0.42601
|
no
| 0
| -0.786497
| null |
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-73G4NR2F2Q-7
|
LYXKV47S
|
Skin
|
Skin Cutaneous Melanoma
|
CDK4
|
SNV
|
p.R24L
|
2
|
ALDPHSGHFV
|
ARDPHSGHFV
| 10
|
12
|
57751647
|
C
|
A
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.085
| 1.2
| 0.065
| 0.469788
| 0.228
| 0.668099
| -4.919637
|
no
| 1
| 4.89147
|
Tumor Driver
|
PMID:28678784
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
|
NDDR-B1DKTHN336-H
|
5DJDBZPW
|
Skin
|
Skin Cutaneous Melanoma
|
SYTL4
|
SNV
|
p.S363F
|
6
|
GRIAFFLKY
|
GRIAFSLKY
| 9
|
X
|
100687163
|
G
|
A
|
HLA-B27:05
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
MS
| 0.009
| 0.4
| 0.001
| 0.914394
| 3.272
| 0.977758
| 0.117783
|
no
| 1
| -2.573045
| null |
PMID:27869121
|
Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
|
NDDR-VZ6AX01GXJ-0
|
5DJDBZPW
|
Skin
|
Skin Cutaneous Melanoma
|
NCAPG2
|
SNV
|
p.P333L
|
2
|
KLILWRGLK
|
KPILWRGLK
| 9
|
7
|
158680743
|
G
|
A
|
HLA-A03:01
|
CD8
|
ELISPOT
|
patient_TIL
|
peptide_pulsed_APC
|
MS
| 0.184
| 0.4
| 0.122
| 0.435756
| 0.762
| 0.861472
| -3.519785
|
no
| 1
| 2.653482
| null |
PMID:27869121
|
Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
|
NDDR-PBXJS7YJDT-A
|
5DJDBZPW
|
Skin
|
Skin Cutaneous Melanoma
|
AKAP6
|
SNV
|
p.M1482I
|
6
|
KLKLPIIMK
|
KLKLPMIMK
| 9
|
14
|
32822259
|
G
|
C
|
HLA-A03:01
|
CD8
|
ELISPOT
|
patient_TIL
|
peptide_pulsed_APC
|
MS
| 0.006
| 0.12
| 0.001
| 0.468706
| 0.62
| 0.968833
| -0.154151
|
no
| 1
| -0.385819
| null |
PMID:27869121
|
Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
|
NDDR-WKQY9KFRV9-K
|
PKPFBJDF
|
Skin
|
Skin Cutaneous Melanoma
|
NOP16
|
SNV
|
p.P169L
|
9
|
SPGPVKLEL
|
SPGPVKLEP
| 9
|
5
|
176384171
|
G
|
A
|
HLA-B07:02
|
CD8
|
ELISPOT
|
patient_TIL
|
peptide_pulsed_APC
|
MS
| 0.011
| 0.7
| 0.028
| 0.235061
| 0.112
| null | -4.500819
|
no
| 1
| 2.721895
| null |
PMID:27869121
|
Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
|
NDDR-C98AVT8VA9-K
|
I4HS6WN2
|
Skin
|
Skin Cutaneous Melanoma
|
CSNK1A1
|
SNV
|
p.S27L
|
2
|
GLFGDIYLA
|
GSFGDIYLA
| 9
|
5
|
149550885_149550886
|
TC
|
CT
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.052
| 1.5
| 0.046
| 0.590849
| -0.414
| 0.312295
| -4.006284
|
no
| 1
| 3.029707
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-FF8XNFEPVF-X
|
74LV6E74
|
Skin
|
Skin Cutaneous Melanoma
|
MATN2
|
SNV
|
p.E226K
|
1
|
KTLTSVFQK
|
ETLTSVFQK
| 9
|
8
|
97931486
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.004
| 0.01
| 0.001
| 0.441139
| 0.686
| 0.926989
| -3.102342
|
no
| 1
| 2.156137
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-894FCPT0FK-1
|
74LV6E74
|
Skin
|
Skin Cutaneous Melanoma
|
CDK12
|
SNV
|
p.E928K
|
5
|
CILGKLFTK
|
CILGELFTK
| 9
|
7
|
40063036
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.279
| 1.1
| 0.021
| 0.14316
| 0.56
| 0.34099
| -0.327213
|
no
| 1
| 2.569549
|
Tumor Driver
|
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-AYRXPFMZNE-W
|
74LV6E74
|
Skin
|
Skin Cutaneous Melanoma
|
CDK12
|
SNV
|
p.E928K
|
5
|
CILGKLFTKK
|
CILGELFTKK
| 10
|
7
|
40063036
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 1.908
| 1.2
| 0.466
| 0.20399
| 0.56
| 0.794302
| 0.048869
|
no
| 0
| 2.569549
|
Tumor Driver
|
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-YRY5RYAEAT-A
|
I4HS6WN2
|
Skin
|
Skin Cutaneous Melanoma
|
CSNK1A1
|
SNV
|
p.S27L
|
2
|
GLFGDIYLAI
|
GSFGDIYLAI
| 10
|
5
|
149550885_149550886
|
TC
|
CT
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.369
| 0.8
| 0.185
| 0.573459
| 0.656
| 0.921601
| -3.064454
|
no
| 1
| 3.029707
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-EMJNAQ3KAZ-G
|
I4HS6WN2
|
Skin
|
Skin Cutaneous Melanoma
|
HAUS3
|
SNV
|
p.T160A
|
7
|
ILNAMIAKI
|
ILNAMITKI
| 9
|
4
|
2240469
|
T
|
C
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.43
| 0.5
| 0.15
| 0.647834
| 0.322
| 0.879551
| 0.750579
|
no
| 1
| 0.52195
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-BGR5R73328-J
|
74LV6E74
|
Skin
|
Skin Cutaneous Melanoma
|
MATN2
|
SNV
|
p.E226K
|
1
|
KTLTSVFQKK
|
ETLTSVFQKK
| 10
|
8
|
97931486
|
G
|
A
|
HLA-A11:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.054
| 0.01
| 0.069
| 0.448778
| 0.686
| 0.963817
| -2.580497
|
no
| 0
| 2.156137
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-545JRB33M5-G
|
J5PM7M2Y
|
Skin
|
Skin Cutaneous Melanoma
|
PLEKHM2
|
SNV
|
p.H1005Y
|
10
|
LTDDRLFTCY
|
LTDDRLFTCH
| 10
|
1
|
15732428
|
C
|
T
|
HLA-A01:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.009
| 0.01
| 0.006
| 0.695479
| 2.652
| 0.412145
| -4.333653
|
no
| 0
| 5.051104
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-F477MEXVTB-T
|
I4HS6WN2
|
Skin
|
Skin Cutaneous Melanoma
|
GAS7
|
SNV
|
p.H225Y
|
9
|
SLADEAEVYL
|
SLADEAEVHL
| 10
|
17
|
9934186
|
G
|
A
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.095
| 2.5
| 0.045
| 0.343229
| 1.054
| 0.969244
| -0.408968
|
no
| 1
| 5.458259
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-1NGBH26P25-G
|
J5PM7M2Y
|
Skin
|
Skin Cutaneous Melanoma
|
PPP1R3B
|
SNV
|
p.P176H
|
5
|
YTDFHCQYV
|
YTDFPCQYV
| 9
|
8
|
9141125
|
G
|
T
|
HLA-A01:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC
|
none
| 0.224
| 1.3
| 0.005
| 0.684944
| -0.158
| 0.901694
| -0.117783
|
no
| 1
| 2.600531
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-3397S1P89B-T
|
J5PM7M2Y
|
Skin
|
Skin Cutaneous Melanoma
|
PPP1R3B
|
SNV
|
p.P176H
|
5
|
YTDFHCQYVK
|
YTDFPCQYVK
| 10
|
8
|
9141125
|
G
|
T
|
HLA-A01:01
|
CD8
|
ELISPOT, ICS
|
patient_TIL
|
peptide_pulsed_APC, tumor_cells
|
endogenous(HLA-block)
| 0.841
| 1.2
| 0.145
| 0.480959
| -0.008
| 0.912707
| 0.144291
|
no
| 1
| 2.600531
| null |
PMID:23644516
|
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
|
NDDR-4H8V6XSZ4F-X
|
6K4YGFNF
|
Skin
|
Skin Cutaneous Melanoma
|
KIF16B
|
SNV
|
p.L1009P
|
2
|
APARLERRHSA
|
ALARLERRHSA
| 11
|
20
|
16378976
|
A
|
G
|
HLA-B07:02
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.459
| 0.7
| 2.211
| 0.022523
| -0.818
| 0.78183
| -3.671241
|
no
| 0
| 1.905253
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-1C3G4QSC15-G
|
6K4YGFNF
|
Skin
|
Skin Cutaneous Melanoma
|
FLNA
|
SNV
|
p.R2049C
|
1
|
CVRVSGQGL
|
RVRVSGQGL
| 9
|
X
|
154353082
|
G
|
A
|
HLA-B07:02
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 1.384
| 1.8
| 0.386
| 0.063144
| 1.114
| 0.953143
| 2.305479
|
no
| 0
| 7.162795
|
Other Tumor Driver
|
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-WYJW76M06R-8
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
PDS5A
|
SNV
|
p.Y1000F;H1007Y
|
1,8
|
FVVPYMIYLL
|
YVVPYMIHLL
| 10
| null | null | null | null |
HLA-C03:03
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 4.104
| 4.5
| 0.127
| 0.088732
| 0.976
| 0.971609
| 1.044545
|
yes
| 0
| 3.19243
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-XJ3RMEC41A-S
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MAGEA6
|
SNV
|
p.E168K
|
1
|
KVDPIGHVY
|
EVDPIGHVY
| 9
|
X
|
152767149
|
C
|
T
|
HLA-A01:01
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.011
| 0.02
| 0.006
| 0.538203
| 2.85
| 0.975792
| 0.606136
|
no
| 0
| 2.919136
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-BS3218G751-C
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MAGEA6
|
SNV
|
p.E168K
|
1
|
KVDPIGHVYIF
|
EVDPIGHVYIF
| 11
| null | null | null | null |
HLA-C05:01
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.207
| 20
| 0.147
| 0.218765
| 2.46
| 0.972332
| -1.486205
|
no
| 0
| 2.919136
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-YXV2AQ4573-E
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MAGEA6
|
SNV
|
p.E168K
|
3
|
LMKVDPIGHVY
|
LMEVDPIGHVY
| 11
| null | null | null | null |
HLA-B15:01
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.178
| 0.04
| 0.557
| 0.094909
| 3.084
| 0.975792
| -1.548041
|
no
| 0
| 2.919136
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-0CQM64X89C-U
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MED13
|
SNV
|
p.P1691S
|
6
|
SVQIISCQY
|
SVQIIPCQY
| 9
| null | null | null | null |
HLA-A30:02
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.122
| 2.5
| 0.031
| 0.996467
| 3.044
| 0.965587
| 0.541341
|
no
| 0
| 2.53319
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-8V8HWA94GP-6
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MED13
|
SNV
|
p.P1691S
|
5
|
VQIISCQY
|
VQIIPCQY
| 8
|
17
|
61961773
|
G
|
A
|
HLA-A30:02
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 1.365
| 4
| 11.228
| 0.965486
| 3.326
| 0.965587
| 0.328301
|
no
| 0
| 2.53319
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-R8DTB8R876-H
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MED13
|
SNV
|
p.P1691S
|
5
|
VQIISCQY
|
VQIIPCQY
| 8
|
17
|
61961773
|
G
|
A
|
HLA-B15:01
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.34
| 0.12
| 0.377
| 0.395824
| 3.326
| 0.965587
| 0.102098
|
no
| 0
| 2.53319
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-NG120S2XBY-F
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MED13
|
SNV
|
p.P1691S
|
7
|
VSVQIISCQY
|
VSVQIIPCQY
| 10
| null | null | null | null |
HLA-A30:02
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.491
| 3.5
| 1.446
| 0.992012
| 3.218
| 0.965587
| -0.085823
|
no
| 0
| 2.53319
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-HHJP6E4WJE-W
|
TOGZJCOT
|
Skin
|
Skin Cutaneous Melanoma
|
MED13
|
SNV
|
p.P1691S
|
7
|
VSVQIISCQY
|
VSVQIIPCQY
| 10
| null | null | null | null |
HLA-A01:01
|
CD8
|
multimer, ELISPOT
|
PBMC_pre, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.715
| 0.12
| 1.623
| 0.058955
| 3.218
| 0.965587
| 0.035591
|
no
| 0
| 2.53319
| null |
PMID:26901407
|
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
|
NDDR-NATBNFYEAK-1
|
YQSS3IYL
|
Ovary
|
Ovarian Cancer
|
HS6ST1
|
SNV
|
p.S405I
|
4
|
DYMIHIIEKW
|
DYMSHIIEKW
| 10
|
2
|
128268184
|
C
|
A
|
HLA-A23:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.328
| 0.9
| 0.215
| 0.596565
| 0.846
| 0.959502
| 0.291755
|
no
| 0
| 4.582285
| null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-BHHDNDR6ZQ-7
|
VMHDDH4X
|
Ovary
|
Ovarian Cancer
|
COPG2
|
SNV
|
p.T37I
|
1
|
IPINPRRCL
|
TPINPRRCL
| 9
|
7
|
130666910
|
G
|
A
|
HLA-B07:02
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.025
| 0.06
| 0.434
| 0.808351
| 0.486
| 0.764573
| 0.083382
|
no
| 0
| 3.153886
| null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-RABCTRZ18B-T
|
TKJU56TT
|
Ovary
|
Ovarian Cancer
|
SEPT9
|
SNV
|
p.R289H
|
7
|
SILEQMHRK
|
SILEQMRRK
| 9
| null | null | null | null |
HLA-A11:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.02
| 0.6
| 0.128
| 0.189973
| 0.682
| null | -1.848455
|
no
| 1
| null | null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-81PF6HAJE6-H
|
Q2ITNIFI
|
Ovary
|
Ovarian Cancer
|
PDPN
|
SNV
|
p.G222C
|
3
|
FICAIIVVV
|
FIGAIIVVV
| 9
|
1
|
13614365
|
G
|
T
|
HLA-A02:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 1.217
| 0.4
| 0.024
| 0.68459
| 0.196
| 0.680153
| 0.893544
|
no
| 0
| 2.404058
| null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-WAWJVEYCNM-3
|
Q2ITNIFI
|
Ovary
|
Ovarian Cancer
|
KIR2DS4
|
SNV
|
p.I7S
|
1
|
SMACVGFFL
|
IMACVGFFL
| 9
| null | null | null | null |
HLA-A02:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 1.021
| 1.9
| 0.068
| 0.363276
| 1.164
| 0.623868
| -0.075436
|
no
| 0
| -5.058894
| null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-B9FTPHZX9N-4
|
GNQ75CJK
|
Ovary
|
Ovarian Cancer
|
USP47
|
SNV
|
p.V170L
|
5
|
TSDYLSQSY
|
TSDYVSQSY
| 9
|
11
|
11892058
|
G
|
C
|
HLA-A01:01
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.002
| 0.4
| 0.004
| 0.252534
| 2.636
| 0.971324
| 0
|
no
| 0
| 0.7376
| null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-8KVBFCA09D-V
|
4DKUZH62
|
Ovary
|
Ovarian Cancer
|
ODZ3
|
SNV
|
p.A2490V
|
9
|
GAQSWLWFV
|
GAQSWLWFA
| 9
|
4
|
182799720
|
C
|
T
|
HLA-A02:11
|
CD8
|
ELISPOT, ICS, multimer
|
PBMC_pre
|
peptide_pulsed_APC
|
none
| 0.923
| 0.7
| 0.142
| 0.975253
| 0.216
| null | -1.199847
|
yes
| 0
| null | null |
PMID:29545564
|
Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
|
NDDR-453FFPEY00-B
|
YG2NSK3U
|
Brain
|
Glioblastoma (GBM)
|
IDH1
|
SNV
|
p.R132H
|
10
|
GWVKPIIIGH
|
GWVKPIIIGR
| 10
|
2
|
208248388
|
C
|
T
|
HLA-B58:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 29.107
| 49
| 20.4
| 0.019775
| -0.336
| 0.868231
| -0.230244
|
yes
| 0
| 5.024923
|
Tumor Driver
|
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-W3ZRQB9QB9-K
|
TBH3PNXF
|
Brain
|
Glioblastoma (GBM)
|
SLC44A2
|
SNV
|
p.L204M
|
4
|
ITDMVEGAKK
|
ITDLVEGAKK
| 10
| null | null | null | null |
HLA-A03:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 2.002
| 2.5
| 1.811
| 0.177257
| 0.114
| 0.373603
| -0.165362
|
no
| 0
| 5.43825
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-Q35B4A9CVQ-7
|
MYK5YWYV
|
Brain
|
Glioblastoma (GBM)
|
RFX1
|
SNV
|
p.T324M
|
2
|
YMQTASTSYY
|
YTQTASTSYY
| 10
| null | null | null | null |
HLA-A01:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.332
| 1
| 0.059
| 0.130624
| 2.824
| 0.966927
| 2.221616
|
no
| 0
| 1.410422
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-0EZ996H7KA-S
|
MYK5YWYV
|
Brain
|
Glioblastoma (GBM)
|
EPHB3
|
SNV
|
p.R677W
|
7
|
YTERQRWDF
|
YTERQRRDF
| 9
| null | null | null | null |
HLA-A01:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.615
| 5
| 0.469
| 0.021732
| 2.126
| 0.088796
| -0.998957
|
no
| 0
| 2.61188
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-A9KQRJ0YTC-U
|
ZLZLTBFT
|
Brain
|
Glioblastoma (GBM)
|
NUCB1
|
SNV
|
p.V300M
|
8
|
RLRMREHMMK
|
RLRMREHVMK
| 10
| null | null | null | null |
HLA-A03:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.167
| 0.15
| 0.361
| 0.359162
| 0.784
| 0.947325
| -0.247982
|
no
| 0
| 5.924214
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-44QS1THAG3-E
|
F3UNKL3Y
|
Brain
|
Glioblastoma (GBM)
|
RBKS
|
SNV
|
p.T95A
|
7
|
KQNDISAEF
|
KQNDISTEF
| 9
| null | null | null | null |
HLA-B15:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.004
| 0.02
| 0.002
| 0.295377
| 2.718
| 0.966161
| 0.287682
|
no
| 0
| 0.333136
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-6J2G3WKA08-J
|
GVYOONV4
|
Brain
|
Glioblastoma (GBM)
|
SLC9A6
|
SNV
|
p.N572I
|
10
|
SAWLFRMWYI
|
SAWLFRMWYN
| 10
| null | null | null | null |
HLA-A02:01
|
CD8
|
ICS
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 13.515
| 6
| 1.186
| 0.176609
| 1.012
| 0.022848
| -1.778226
|
no
| 0
| 2.120799
| null |
PMID:30733620
|
Actively personalized vaccination trial for newly diagnosed glioblastoma
|
NDDR-EDQDWAWTP4-F
|
PFMINZ56
|
Breast
|
Breast Cancer
|
ECPAS
|
SNV
|
p.S186F
|
10
|
MPYGYVLNEF
|
MPYGYVLNES
| 10
|
9
|
111437072_111437073
|
CA
|
TT
|
HLA-B35:01
|
CD8
|
ELISPOT, 4-1BB
|
patient_TIL, TCR_clone
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.056
| 0.05
| 0.018
| 0.478653
| 2.356
| 0.422068
| -4.303582
|
yes
| 0
| 4.401606
| null |
PMID:29867227
|
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
|
NDDR-Y3TJTRGEMA-S
|
PFMINZ56
|
Breast
|
Breast Cancer
|
CADPS2
|
SNV
|
p.R1266H
|
8
|
TYDTVHRHL
|
TYDTVHRRL
| 9
|
7
|
122320259
|
C
|
T
|
HLA-C04:01
|
CD8
|
ELISPOT, 4-1BB
|
patient_TIL, TCR_clone
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.006
| 25
| 0.001
| 0.660042
| 0.732
| 0.958242
| -0.287682
|
no
| 0
| 3.089786
| null |
PMID:29867227
|
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
|
NDDR-9MF2CZ9EEC-U
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
PORCN
|
SNV
|
p.H346Y
|
8
|
LLHGFSFYL
|
LLHGFSFHL
| 9
|
X
|
48515902
|
C
|
T
|
HLA-A02:01
|
CD8
|
multimer, 51Cr
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.086
| 0.15
| 0.015
| 0.734435
| 1.068
| 0.977941
| 0.059898
|
no
| 1
| 1.886384
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-7HFGTRT2KG-Y
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
AKAP9
|
SNV
|
p.L947F
|
5
|
RLSDFSEQL
|
RLSDLSEQL
| 9
|
7
|
92002801
|
C
|
T
|
HLA-A02:01
|
CD8
|
multimer, 51Cr
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.024
| 0.4
| 0.069
| 0.499613
| 1.168
| 0.977036
| -0.223144
|
no
| 1
| 2.055005
|
Other Tumor Driver
|
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-R6WWVF6EQ6-H
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
RASAL2
|
SNV
|
p.P637S
|
4
|
IMSSSLFNL
|
IMSPSLFNL
| 9
|
1
|
178452552
|
C
|
T
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 0.236
| 0.6
| 0.066
| 0.306679
| 1.032
| 0.969002
| 1.352958
|
no
| 1
| 1.331619
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-108MYSE1VC-U
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
CDKN2A
|
SNV
|
p.P114L
|
2
|
LLVDLAEEL
|
LPVDLAEEL
| 9
|
9
|
21971018
|
G
|
A
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 0.1
| 2.5
| 0.174
| 0.478684
| 1.164
| 0.957983
| -4.712319
|
no
| 0
| 1.258459
|
Tumor Driver
|
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-1G2Z2Z3NBX-E
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
PDE7B
|
SNV
|
p.G113R
|
1
|
RMWDFDIFL
|
GMWDFDIFL
| 9
|
6
|
136149105
|
G
|
A
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 0.022
| 0.09
| 0.005
| 0.719792
| 1.63
| 0.968043
| -0.127833
|
no
| 0
| -1.260168
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-SEA7CN1KAX-E
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
GCN1L1
|
SNV
|
p.P274L
|
6
|
SLLRSLENV
|
SLLRSPENV
| 9
|
12
|
120177464
|
G
|
A
|
HLA-A02:01
|
CD8
|
multimer, 51Cr
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.06
| 0.4
| 0.081
| 0.546661
| 0.416
| null | -0.559616
|
no
| 1
| null | null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-EZBD3HKP1K-1
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
SOCS6
|
SNV
|
p.P134L
|
9
|
SLRSHHYSL
|
SLRSHHYSP
| 9
|
18
|
70325069
|
C
|
T
|
HLA-B08:01
|
CD8
|
multimer, 51Cr
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.006
| 0.6
| 0.023
| 0.480798
| 1.118
| 0.409931
| -5.372961
|
yes
| 1
| 3.067294
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-5GDBWJVZ1H-Z
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
POGK
|
SNV
|
p.P46L
|
3
|
WVLALFDEV
|
WVPALFDEV
| 9
|
1
|
166846616
|
C
|
T
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
none
| 3.02
| 4.5
| 0.733
| 0.347158
| 0.314
| 0.288239
| -0.050995
|
no
| 0
| 3.56306
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-T0AFTDJ9PD-V
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
ZDBF2
|
SNV
|
p.S2228L
|
3
|
YILKYSVFL
|
YISKYSVFL
| 9
|
2
|
206311211
|
C
|
T
|
HLA-A02:01
|
CD8
|
multimer, 51Cr
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC, TMC_minigene
|
TMC
| 0.193
| 0.5
| 0.027
| 0.61301
| 0.96
| 0.963955
| -0.179728
|
no
| 1
| -0.664534
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-47041KC807-I
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
GAS7
|
SNV
|
p.S270F
|
1
|
FLGEAWAQV
|
SLGEAWAQV
| 9
|
17
|
9934242
|
G
|
A
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 0.055
| 0.9
| 0.392
| 0.592199
| -0.264
| 0.969671
| -0.828949
|
no
| 0
| 5.458259
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-JV00FYYZJR-8
|
6TP4IBLE
|
Skin
|
Skin Cutaneous Melanoma
|
PNPLA4
|
SNV
|
p.P100S
|
3
|
ILSPSAHEL
|
ILPPSAHEL
| 9
|
X
|
7921826
|
G
|
A
|
HLA-A02:01
|
CD8
|
multimer
|
PBMC_pre, PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 0.024
| 1.4
| 0.196
| 0.431042
| 0.922
| 0.976745
| -0.432864
|
no
| 0
| 2.462092
| null |
PMID:31685621
|
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
|
NDDR-N6NTA1JDTE-W
|
352WTYXA
|
Ovary
|
Ovarian Cancer
|
PPM1F
|
SNV
|
p.C259Y
|
7
|
FLAPLFLVLL
|
FLAPLFCVLL
| 10
|
5
|
88203038
|
T
|
G
|
HLA-A24:02
|
CD8
|
ELISPOT
|
PBMC_postVax, patient_TIL
|
peptide_pulsed_APC
|
none
| 8.36
| 3
| 1.457
| 0.027011
| 0.736
| null | -0.252377
|
no
| 0
| 0.780394
| null |
PMID:32660279
|
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
|
NDDR-MCK2ZAJ8GQ-7
|
R7NU4BAT
|
Brain
|
Glioblastoma (GBM)
|
WDR63
|
SNV
|
p.T690M
|
8
|
FYNDIILMV
|
FYNDIILTV
| 9
|
1
|
85124208
|
C
|
T
|
HLA-C06:02
|
CD8
|
ELISPOT
|
PBMC_postVax
|
peptide_pulsed_APC
|
none
| 0.042
| 34
| 0.001
| 0.937943
| 0.026
| null | 0.518794
|
no
| 0
| null | null |
PMID:30906654
|
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
|
NDDR-S6DN480CYD-V
|
XD6MQQ3M
|
Ovary
|
Ovarian Cancer
|
SSC4D
|
SNV
|
p.D85Y
|
9
|
YGTGHILLY
|
YGTGHILLD
| 9
|
7
|
76397626
|
C
|
A
|
HLA-B35:01
|
CD8
|
4-1BB, ICS
|
PBMC_pre
|
peptide_pulsed_APC, tumor_cells
|
none
| 0.347
| 5
| 0.095
| 0.34794
| 2.496
| 0.067292
| -5.180179
|
yes
| 0
| 1.241352
| null |
PMID:31069153
|
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
|
NDDR-VS85BXHK0E-W
|
XD6MQQ3M
|
Ovary
|
Ovarian Cancer
|
SSC4D
|
SNV
|
p.D85Y
|
9
|
YGTGHILLY
|
YGTGHILLD
| 9
|
7
|
76397626
|
C
|
A
|
HLA-C12:03
|
CD8
|
4-1BB, ICS
|
PBMC_pre
|
peptide_pulsed_APC, tumor_cells
|
none
| 0.117
| 18
| 0.008
| 0.062591
| 2.496
| 0.067292
| -5.774366
|
yes
| 0
| 1.241352
| null |
PMID:31069153
|
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
|
NDDR-HR56JF3PKD-V
|
XD6MQQ3M
|
Ovary
|
Ovarian Cancer
|
NAV1
|
SNV
|
p.K349M
|
1
|
MAKAKAVAL
|
KAKAKAVAL
| 9
| null | null | null | null |
HLA-B35:01
|
CD8
|
4-1BB, ICS
|
PBMC_pre
|
peptide_pulsed_APC, tumor_cells
|
none
| 0.841
| 1.2
| 1.189
| 0.061466
| 1.048
| 0.941944
| -1.781601
|
yes
| 0
| 0.481402
| null |
PMID:31069153
|
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
|
NDDR-C5YZS7EBSD-V
|
XD6MQQ3M
|
Ovary
|
Ovarian Cancer
|
TRO
|
SNV
|
p.S598C
|
5
|
SVGACGFSY
|
SVGASGFSY
| 9
|
X
|
54930991
|
C
|
G
|
HLA-B35:01
|
CD8
|
4-1BB, ICS
|
PBMC_pre
|
peptide_pulsed_APC, tumor_cells
|
none
| 1.793
| 2.5
| 0.289
| 0.02987
| 2.782
| null | 1.156591
|
yes
| 0
| 1.602932
| null |
PMID:31069153
|
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
|
End of preview.